3017 Terasaki Life Sciences Building
610 Charles E. Young Drive East
Los Angeles, CA 90095
Recent Publications
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Proceedings of the National Academy of Sciences (PNAS)
A new low-cost assay that sequences Cell-free DNA (cfDNA) methylome from blood called MethylScan to detect and monitor a broad range of diseases, including ovarian cancer.
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade
Proceedings of the National Academy of Sciences (PNAS)
In RB1 deficient prostate, lung, and adnexa cancer, E2F3 inhibition suppresses tumor cell growth. This synthetic lethal interaction can be targeted via pyrimidine synthesis blockade.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Science Translational Medicine
CAR-αVEGF T cells showed increased efficacy against ovarian cancer and glioma tumor models with minimal damage compared to control CAR T cell treatment. CAR-αVEGF T cells exhibit great therapeutic potential.
Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma
Experimental Hematology & Oncology
AlloMCAR-NKT cells have to potential to provide a safe and effective off-the-shelf cellular immunotherapy for the treatment of uterine/endometrial carcinomas as well as other solid tumors characterized by an immunosuppressive microenvironment.
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
Med
Exploriong the alternative approach of using allogenic CAR-engineered invariant natural killer T (AlloCAR-NKT) cells to not only combat chemo resistant ovarian cancer tumors but also remodel the tumor micro environment.
Tumor extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
eBioMedicine
Tumour-derived extracellular vesicles (EVs) are a promising potential biomarker for epithelial ovarian cancer. Here we deveopled a Surface Protein-mRNA Integration (SPRI) Assay for early detection.
A case series of four patients with recurrent ovarian granulosa cell tumors treated with CDK4/6 inhibitors and estrogen blockade in a pilot study
European Journal of Gynaecological Oncology
There is currently no established optimal treatment for advanced or recurrent granulosa cell tumors (GCTs), making management challenging. Given the success of CDK4/6 inhibitors in hormone receptor-positive breast cancer, we explored their use in GCTs.
Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays
STAR Protocols
Protocol to characterize primary ovarian cancer patient samples and a detalied design and evaluation of various cell-based immunotherapies aimed at targeting primary tumors and the tumor microenvironment through in vitro killing assays.
SUPPORT RESEARCH
Donate
Every donation is gratefully accepted and will be put to use on the work of the lab. There are many ways to donate, and all make a difference. If you share our passion for finding better treatments for women’s cancer, please consider giving hope by donating to this important cause.